Clinical Trials | December 11, 2025
Lilly drug cuts risk of disease progression or death by 80% in trial
The company has unveiled the results of pirtobrutinib from its BRUIN CLL-313 study
The company has unveiled the results of pirtobrutinib from its BRUIN CLL-313 study
India has deep strengths in reverse engineering and API development, while Russia has strong capabilities in certain vaccines, biologicals, and niche therapeutic segments. Collaboration can significantly shorten R&D timelines
Akero became a wholly owned subsidiary of Novo Nordisk
The new site will produce next-generation synthetic medicine active pharmaceutical ingredients
Formycon AG will develop, register, manufacture and supply the product, while Zydus Lifesciences Global FZE, United Arab Emirates will be responsible for the commercialization of FYB206 in the defined territories
Dr Reddy’s will pay Immutep US$ 20 million upfront and could deliver as much as US$ 349.5 million in regulatory and commercial milestones
This collaboration sets the stage for WuXi Biologics’ first integrated CRDMO center in the region
The study met its primary endpoint and all 11 secondary efficacy endpoints
It's a development that marks a potential breakthrough for people living with the rare and debilitating disease Duchenne muscular dystrophy (DMD)
MRI is particularly valuable in pediatric care due to its non-invasive nature
Subscribe To Our Newsletter & Stay Updated
